Help | Scores |Exit
Fragmin | Magnex | Solu Medrol
Benazepril Drug Name:  
A|B|C|D|E|F|G|H|I|K|L|M|N|O|P|Q|R|S|T|V|Z
Indications
Dosages
Interactions
Precautions
Contraindications
Adverse Reactions
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interactions:

Allopurinol

  • Adverse Effect: hypersensitivity reactions (Stevens-Johnson syndrome, skin eruptions)  
  • Clinical Management: If these drugs are used concurrently, monitor for hypersensitivity reactions.

    Amiloride

  • Adverse Effect: hyperkalemia  
  • Clinical Management: Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.

    Aspirin

  • Adverse Effect: decreased benazepril effectiveness  
  • Clinical Management: Although studies have suggested an interaction between Benazepril and aspirin, the clinician should weigh the benefits against the risks of combining these two agents.

    Bumetanide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the Benazepril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Celecoxib

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Chlorthalidone

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the Benazepril in evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Clopamide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of Benazepril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Diclofenac Preps.

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Erythropoietin

  • Adverse Effect: higher maintenance doses of erythropoietin to maintain the target hematocrit  
  • Clinical Management: Monitor patients receiving Benazepril for erythropoietin efficacy. When given concomitantly, doses of erythropoietin may be higher than expected.

    Flurbiprofen

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Frusemide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the Benazepril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Ibuprofen

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Indapamide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the Benazepril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Indomethacin

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Ketoprofen

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Ketorolac

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Lithium

  • Adverse Effect: Lithium toxicity (weakness, tremor, excessive thirst, confusion) and/or nephrotoxicity  
  • Clinical Management: The combination of lithium and Benazepril should be avoided if possible, though the choice of an alternative antihypertensive agent that does not interact with lithium is limited. If lithium and Benazepril are used concurrently, serum lithium levels should be closely monitored and the patient followed up for any symptoms of lithium toxicity.

    Mefenamic Acid

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Meloxicam

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Nabumetone

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Naproxen

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Nimesulide

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Oxyphenbutazone

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Paracetamol

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Phenacetin

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Phenylbutazone

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Piroxicam

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Rofecoxib

  • Adverse Effect: Increase in mean arterial pressure   #
  • Clinical Management: Monitor for the increase in arterial pressure and adjust the dose accordingly when ACE inhibitors like Benazepril and Rofecoxib are administered together.

    Spironolactone

  • Adverse Effect: hyperkalemia  
  • Clinical Management: Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.

    Tenoxicam

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Xipamide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the Benazepril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.
  • Bacitracin
    Beclomethasone Dipropionate
    Beclomethasone Dipropionate Monohydrate
    Betamethasone
    Betamethasone Dipropionate
    Bisacodyl
    Bismuth Subsalicylate
    Brompheniramine Maleate
    Budesonide
    Bumetanide
    Busulfan
    Betaxolol
    Bethanechol
    Bromocriptine
    Bupivacaine
    Buprenorphine
    BCG Vaccine
    Bupropion hcl
    Buspirone
    Busulphan
    BCG-TB
    Bacampicillin
    Baclofen
    Bambuterol
    Benazepril
    Benidipine
    Benzathine Penicillin
    Benzocaine
    Benzoyl Peroxide
    Benzydamine Hcl -OP
    Benzydamine VU
    Benzyl Benzoate
    Benzyl Penicillin
    Betahistine
    Betamethasone - Ocular
    Betamethasone - Topical
    Bezafibrate
    Bifonazole
    Bisoprolol
    Botropase
     
    Disclaimer